← All trials
NCT07002346
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2025
- Primary completion
- Jun 1, 2027
- Completion date
- Jun 1, 2029
- First posted
- Jun 3, 2025
- Last posted
- Jun 3, 2025
- Enrollment
- 226
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Sun Yat-Sen UniversityCollaborator
- Jiangsu Cancer Institute & HospitalCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Jiao Tong UniversityCollaborator
- Fudan UniversityCollaborator
- The International Peace Maternity & Child Health Hospital of China welfare instituteCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Zhengzhou UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Peking UniversityCollaborator
- Peking UniversityCollaborator
- Henan Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Wuhan Central HospitalCollaborator
- Henan Provincal People's HospitalCollaborator
- Wuhan UniversityCollaborator
- Wuhan UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.